ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 04 Jan 2022
Last Updated on 02 Jan 2024
A- A+
Tyrosine Kinase inhibitors, Immune Checkpoint inhibitors and Everolimus for treating advanced renal cell cancer Guidance is outdated and has been withdrawn on 31 Aug 2022.
Please refer to the updated recommendations on Update of MOH List of Subsidised Drugs to include treatments for various cancer conditions here. The Plain English Summary (PES) has been updated on 31 August 2022.
PES Treatments for advanced renal cell carcinoma (Updated 2 Jan 2024) Tyrosine Kinase inhibitors, Immune checkpoint inhibitors and everolimus for treating advanced RCC (Withdrawn 31 Aug 2022)